Claims
- 1. An ophthalmic composition, comprising:a) at least one basic active; b) a polyanionic polymer; c) an ion exchange resin; and d) a pH adjusting agent, wherein said agent is present in an amount sufficient to adjust the pH of the composition to between about 3.5 and about 9.5 and wherein the pH adjusting agent is a basic amine and does not substantially disrupt interaction between the basic active and the ion exchange resin.
- 2. The composition according to claim 1, wherein the basic active is selected from the group consisting of glaucoma agents, muscarinics, carbonic anhydrase inhibitors, dopaminergic agonists and antagonists, post surgical α-2 agonists, anti-infectives, non-steroidal and steroidal anti-inflammatories, prostaglandins, proteins, growth factors, anti-allergics, beta blockers, and mixtures thereof.
- 3. The composition according to claim 2, wherein the basic active is a beta blocker.
- 4. The composition according to claim 3, wherein the beta blocker is levobetaxolol.
- 5. The composition according to claim 3, wherein the beta blocker is present at a concentration between about 0.1% and about 5.0%.
- 6. The composition according to claim 1, wherein the pH adjusting agent is selected from the group consisting of ammonia, tromethamine (TRIS or Tris(hydroxymethyl)aminomethan), triethanolamine (TEA), N-2-hydroxyethyl piperazine-N′-2-ethanesulfonic acid (HEPES), and mixtures thereof.
- 7. The composition according to claim 1, wherein the pH adjusting agent further comprises hydrochloric acid.
- 8. The composition according to claim 1, whereinsaid pH adjusting agent is present in an amount sufficient to adjust the pH of the composition to between about 5 and about 9.
- 9. The composition according to claim 8, whereinsaid pH adjusting agent is present in an amount sufficient to adjust the pH of the composition to between about 6 and about 8.
- 10. The composition according to claim 9, whereinsaid pH adjusting agent is present in an amount sufficient to adjust the pH of the composition to about 6.5.
- 11. The composition according to claim 1, wherein the composition is in the form of an aqueous gel, a pourable aqueous dispersion, or an anhydrous salt.
- 12. The composition according to claim 1, further comprising one or more preservatives.
- 13. The composition according to claim 1, further comprising one or more tonicity agents.
- 14. An opthalmic composition comprising:levobetaxolol hydrochloride; poly(styrene divinylbenzene) sulfonic acid; carbomer; mannitol; boric acid; disodium edetate; benzalkonium chloride; N-lauroylsarcosine; and tromethamine, and optionally hydrochloric acid, in an amount sufficient to adjust the pH of the composition to between about 6.5.
- 15. The composition according to claim 1, wherein said basic active comprises betaxolol, and prostaglandin or prostaglandin analog.
- 16. The composition according to claim 15, wherein said betaxolol is levobetaxolol, and said prostaglandin analog is cloprostenol, fluprostenol, latanoprost, or travoprost.
- 17. The composition according to claim 15, wherein said prostaglandin analog is travoprost.
- 18. A method of treating an eye in need thereof, which comprises administering topically to an affected eye, an ophthalmic composition comprising:a) at least one basic active; b) a polyanionic polymer; c) an ion exchange resin; and d) a pH adjusting agent, wherein said agent is present in amount sufficient to adjust the pH of the composition to between about 3.5 and about 9.5; and wherein the pH adjusting agent is a basic amine and does not substantially disrupt interaction between the basic active and the ion exchange resin.
- 19. The method according to claim 18, wherein the basic active is selected from the group consisting of glaucoma agents, muscarinics, carbonic anhydrase inhibitors, dopaminergic agonists and antagonists, post surgical α-2 agonists, anti-infectives, non-steroidal and steroidal anti-inflammatories, prostaglandins, proteins, growth factors, anti-allergics, beta blockers and mixtures thereof.
- 20. The method according to claim 1, wherein the basic active is a beta blocker.
- 21. The method according to claim 20, wherein the beta blocker is levobetaxolol.
- 22. The method according to claim 20, wherein the beta blocker is present at a concentration between about 0.1% and about 5.0%.
- 23. The method according to claim 19, wherein the pH adjusting agent is selected from the group consisting of ammonia, tromethamine (TRIS or Tris(hydroxymethyl)aminomethan), triethanolamine (TEA), N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid), (HEPES), and mixtures thereof.
- 24. The method according to claim 18, wherein the pH adjusting agent further comprises hydrochloric acid.
- 25. The method according to claim 18, whereinsaid pH adjusting agent is present in an amount sufficient to adjust the pH of the composition to between about 5 and about 9.
- 26. The method according to claim 25, whereinsaid pH adjusting agent is present in an amount sufficient to adjust the pH of the composition to between about 6 and about 8.
- 27. The method according to claim 26, whereinsaid pH adjusting agent is present in an amount sufficient to adjust the pH of the composition to about 6.5.
- 28. The method according to claim 19, wherein the composition is in the form of an aqueous gel, a pourable aqueous dispersion, or an anhydrous salt.
- 29. The method according to claim 19, further comprising one or more preservatives.
- 30. The method according to claim 19, farther comprising one or more tonicity agents.
- 31. The method according to claim 19, wherein said basic active comprises betaxolol, and prostaglandin or prostaglandin analog.
- 32. The method according to claim 33, wherein said betaxolol is levobetaxolol, and said prostaglandin analog is cloprostenol, fluprostenol, latanoprost, or travoprost.
- 33. The composition according to claim 33, wherein said prostaglandin analog is travoprost.
Parent Case Info
This application claim the benefit of U.S. provisional application Ser. No. 60/101,959, filed Sep. 25, 1998
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/US99/21957 |
|
WO |
00 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO00/18316 |
4/6/2000 |
WO |
A |
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4911920 |
Jani et al. |
Mar 1990 |
A |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/101959 |
Sep 1998 |
US |